# Human cytomegalovirus strain-specific differences in protein expression of type I IFN pathway proteins do not impact virus replication

**Authors:** Katie A. Latham, Timothy K. Soh, Richard J. Stanton, Jens B. Bosse, Steve Goodbourn, Blair L. Strang

PMC · DOI: 10.1099/acmi.0.001104.v3 · Access Microbiology · 2026-02-19

## TL;DR

This study finds that different strains of human cytomegalovirus affect type I IFN pathway proteins but do not impact virus replication.

## Contribution

The study reveals strain-specific differences in IFN pathway protein expression without affecting HCMV replication.

## Key findings

- HCMV strains AD169 and Merlin show modest differences in IFN-associated protein expression.
- No significant differences in IFN-β RNA production or virus replication were observed between strains.
- Multiplicity of infection influences IRF3 expression in HCMV-infected cells.

## Abstract

The type I IFN response is crucial for cells to restrict viral replication during infection. Many viruses, including human cytomegalovirus (HCMV), have evolved mechanisms to antagonize the type I IFN response. We have previously observed an increase in protein expression of certain IFN-stimulated genes when comparing the high-passage HCMV strain AD169 to the low-passage strain HCMV Merlin, suggesting that AD169 is defective in its ability to inhibit type I IFN function. To better understand HCMV interaction with the type I IFN response, we examined expression of cellular and viral proteins expressed in Merlin- and AD169-infected cells associated with IFN production and signalling. HCMV IFN antagonists expressed by both viruses had differences in amino acids throughout their protein sequences, although analysis using AlphaFold revealed that there was likely to be no obvious differences in the overall structure of these proteins. Analysis of quantitative mass spectrometry datasets showed modest differences in the expression of cellular IFN-associated proteins between strains. Contrary to previously reported data, we found no obvious loss of IRF3 expression, though this may be due to experimental differences between studies. These data revealed that multiplicity of infection was an important factor in IRF3 expression. We found little or no statistical difference in the production of IFN-β RNA between Merlin- and AD169-infected cells in reverse transcriptase quantitative PCR assays and little or no statistical difference in replication of AD169 and Merlin in virus replication assays. Overall, these data suggest that different strains of HCMV have different, albeit modest, abilities to influence the expression of type I IFN pathway proteins during infection. However, this had no overall impact on the ability of different strains to produce a type I IFN or to replicate.

## Linked entities

- **Genes:** IFNA1 (interferon alpha 1) [NCBI Gene 3439], IRF3 (interferon regulatory factor 3) [NCBI Gene 3661], IFNB1 (interferon beta 1) [NCBI Gene 3456]
- **Proteins:** IRF3 (interferon regulatory factor 3)

## Full-text entities

- **Genes:** IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, Nf2 (neurofibromin 2) [NCBI Gene 18016] {aka merlin}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, MX1 (MX dynamin like GTPase 1) [NCBI Gene 4599] {aka IFI-78K, IFI78, MX, MxA, lncMX1-215}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, JAK1 (Janus kinase 1) [NCBI Gene 3716] {aka AIIDE, JAK1A, JAK1B, JTK3}, STAT2 (signal transducer and activator of transcription 2) [NCBI Gene 6773] {aka IMD44, ISGF-3, P113, PTORCH3, STAT113}, IRF3 (interferon regulatory factor 3) [NCBI Gene 3661] {aka IIAE7}, IFNAR1 (interferon alpha and beta receptor subunit 1) [NCBI Gene 3454] {aka AVP, CRF2-1, IFN-R-1, IFN-alpha-REC, IFNAR, IFNBR}, NF2 (NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor) [NCBI Gene 4771] {aka ACN, BANF, SCH, SWNV, merlin-1}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, Lcp1 (lymphocyte cytosolic protein 1) [NCBI Gene 18826] {aka D14Ertd310e, LCP-1, Pls2, pp65}
- **Diseases:** developmental disabilities (MESH:D002658), congenital disease (MESH:D030342), hearing loss (MESH:D034381), TBS-T (OMIM:615707), microcephaly (MESH:D008831), HFF (MESH:D001734), jaundice (MESH:D007565), LDDT (MESH:D013736), HCMV infection (MESH:D003586), AIDS (MESH:D000163), toxicity (MESH:D064420), cancer (MESH:D009369), Infection (MESH:D007239), birth defects (MESH:D000014)
- **Chemicals:** SDS (MESH:D012967), polyvinylidene difluoride (MESH:C024865), Tween 20 (MESH:D011136), TRIzol (MESH:C411644), CO2 (MESH:D002245), methylcellulose (MESH:D008747), polyacrylamide (MESH:C016679), dexamethasone (MESH:D003907), crystal violet (MESH:D005840), methanol (MESH:D000432), BioRender (-)
- **Species:** Sendai virus [taxon 11191], Human betaherpesvirus 5 (no rank) [taxon 10359], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** AD169 — Mus musculus (Mouse), Hybridoma (CVCL_C5N6), HFFT-TERT — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_TR98), HFF — Homo sapiens (Human), Finite cell line (CVCL_XB54), HFFF — Homo sapiens (Human), Finite cell line (CVCL_9V94), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12917765/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12917765/full.md

## References

44 references — full list in the complete paper: https://tomesphere.com/paper/PMC12917765/full.md

---
Source: https://tomesphere.com/paper/PMC12917765